about
Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.Urine markers in monitoring for prostate cancer.Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients.DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.High-grade urothelial bladder cancer in children: A case report and critical analysis of the literature.The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.Wooden Foreign Body in the Renal Pelvis.Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancerHigh Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cellsTrop-2 plasticity is controlled by epithelial-to-mesenchymal transitionInfiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene FusionRole of early postoperative urethroscopy for urethral vitality assessment after penis replantation
P50
Q24614665-F2F4175C-094F-4D5F-96B3-646CD4124D32Q36546592-A7321B25-C60D-4E8F-97C1-01E011695E83Q37571461-2BF8DF81-F2CC-4CF4-8BA3-766F2ADEBD47Q38410599-3B765DA3-E90E-4BF4-ACCB-24D8157AF5F8Q38893748-CA1E987B-D159-425C-A09E-5CDCAF441395Q38983433-1F15ABEF-681D-45C2-96C1-7E64FC71235FQ38989505-98C1922B-6528-410F-9B12-4DB6DEE25484Q47100889-11BC6A60-86C3-40F1-9CE0-E41B13922EB7Q51333397-46E47957-F99B-4525-B64F-AEF7B8B9ACFAQ52982943-7D6B60E5-4C40-425C-B9FE-B8BDBDA39D4DQ53084143-F08A2E94-D6A9-440B-BC1C-4E87983DFFBEQ61989408-610DF6D0-D2E6-4D3E-B7CD-FB247DDDC28DQ64074308-6B78885E-F5CF-4AEF-9606-7DC8BABE9D6EQ90238110-26C70778-442E-42C2-832E-83DAA8D36CB0Q90458373-970B2828-688D-4321-892A-E2AD778D10B0Q91217936-BAA664D3-4C0B-4FB2-BEC7-E07FE30BAE78
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Milan Kral
@ast
Milan Kral
@en
Milan Kral
@es
Milan Kral
@nl
type
label
Milan Kral
@ast
Milan Kral
@en
Milan Kral
@es
Milan Kral
@nl
prefLabel
Milan Kral
@ast
Milan Kral
@en
Milan Kral
@es
Milan Kral
@nl
P106
P21
P31
P496
0000-0003-1851-5179